Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
GRIN-related Disorders
Interventions
DRUG

Radiprodil

Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.

Trial Locations (15)

3015

ERASMUS Medisch Centrum, Developmental & Genetic pediatrics, Rotterdam

3508

UMC Utrecht - Wilhelmina Kinderziekenhuis, Polikliniek Kinderneurologie, Utrecht

4101

Queensland Children's Hospital, South Brisbane

10032

Columbia University Irving Medical Center, Dept of Neurology, New York

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

28034

Hospital Ruber Internacional, Madrid

50139

Azienda Ospedaliero Universitaria Careggi (AOUC) Firenze - Azienda Ospedaliera Universitaria Meyer, Florence

81377

KBO-Kinderzentrum München gemeinnützige GmbH, München

M5G 1X8

The Hospital for Sick Children (Sick Kids), Toronto

BC V6H 3N1

BC Children's Hospital, Vancouver

04103

Abteilung für Neuropädiatrie, Klinik und Poliklinik für Kinder - und Jugendmedizin, Universitätsklinikum Leipzig, Leipzig

00165

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu, Rome

08950

Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB), Barcelona

G51 4TF

Royal Hospital for Children Glasgow, Glasgow

WC1N 3JH

Great Ormond Street Hospital For Children NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

GRIN Therapeutics, Inc.

INDUSTRY